HemoGenyx Pharmaceuticals Plc (HEMO) AI Stock Analysis

• Market Cap: £36.85M
• Dividend Yield: N/A
• Average Volume (3M): 113.41K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.98
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.42
• Shares Outstanding: 6,041,255
• 10 Day Avg. Volume: 30,447
• 30 Day Avg. Volume: 113,406
• PEG Ratio: 0.08
• Price to Book (P/B): 14.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: 548.00p ▼(-3.52% Downside)

The score is held down primarily by very weak financial performance (no revenue, ongoing losses and cash burn, and increased balance sheet leverage). Technicals add modest pressure due to price sitting below key moving averages and negative MACD, while valuation offers little support given the negative P/E and no dividend yield.

HemoGenyx Pharmaceuticals Plc Business Overview & Revenue Model

Company Description

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

How the Company Makes Money

HemoGenyx Pharmaceuticals Plc Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-631.38K	-639.28K	-645.68K	-2.60M	-283.65K	-350.72K
EBITDA	-6.94M	-4.71M	-5.73M	-3.42M	-2.39M	-1.96M
Net Income	-7.81M	-5.62M	-6.69M	-3.98M	-5.10M	-2.08M
Balance Sheet
Total Assets	3.10M	4.21M	6.11M	7.09M	8.52M	2.66M
Cash, Cash Equivalents and Short-Term Investments	226.73K	159.26K	1.25M	2.53M	6.84M	1.81M
Total Debt	2.20M	2.62M	2.95M	3.42M	10.15K	1.63M
Total Liabilities	3.65M	3.36M	3.32M	3.85M	352.84K	1.79M
Stockholders Equity	-500.15K	897.51K	2.82M	3.28M	8.19M	890.84K
Cash Flow
Free Cash Flow	-5.58M	-4.13M	-6.22M	-3.34M	-3.45M	-1.97M
Operating Cash Flow	-5.57M	-4.12M	-6.11M	-2.91M	-2.63M	-1.80M
Investing Cash Flow	235.15K	-24.90K	-31.94K	-420.25K	-938.95K	-169.68K
Financing Cash Flow	1.91M	3.08M	4.45M	-110.14K	8.78M	3.21M

HemoGenyx Pharmaceuticals Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HVO	73 Outperform	£42.94M	7.77	―	2.94%	11.92%	-33.76%
AREC	56 Neutral	£34.92M	-3.96	-204.29%	―	3.31%	21.91%
APTA	52 Neutral	£26.97M	-6.96	-213.66%	―	39.88%	81.33%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POLB	49 Neutral	£29.28M	-3.77	-46.84%	―	―	―
IMM	46 Neutral	£37.80M	-8.07	-259.88%	―	―	―
HEMO	43 Neutral	£36.85M	-2.82	-609.30%	―	―	―

HemoGenyx Pharmaceuticals Plc Corporate Events

Hemogenyx Sets Early January Date for Admission of New Shares

Hemogenyx Pharmaceuticals has confirmed that the UK Financial Conduct Authority has scheduled an admission hearing for its new ordinary shares on 5 January 2026, with trading in the new shares expected to commence at around 8:00 a.m. on 6 January 2026. The timing update indicates the capital-related process is progressing as planned, with all other terms from the company’s 18 December 2025 announcement remaining unchanged, providing investors and other stakeholders with clarity on the anticipated schedule for the shares’ admission to trading.

Hemogenyx Pharmaceuticals Announces Equity Issuance and Operational Updates

Hemogenyx Pharmaceuticals plc has issued 123,377 new ordinary shares following warrant exercises, restricted stock unit vesting, and obligations under a Deed of Variation. This issuance, raising £190,000 and leading to adjustments in total issued shares and voting rights, reflects the company’s ongoing efforts to fund operational developments and ensure alignment with regulatory requirements, which may strengthen its market positioning and reassure stakeholders.

Hemogenyx Pharmaceuticals Publishes Prospectus for New Share Admission

Hemogenyx Pharmaceuticals has announced the publication of a Prospectus related to the admission of new ordinary shares to the London Stock Exchange. This move involves the conversion of convertible loan notes and the exercise of warrants, with trading expected to commence on 24 November 2025. This development is significant for Hemogenyx as it enhances their market presence and potentially impacts their financial standing by increasing the number of shares available for trading.

Hemogenyx Pharmaceuticals Advances CAR-T Therapy Trial with DSMB Approval

Hemogenyx Pharmaceuticals announced that the Data Safety Monitoring Board has approved the continuation of its Phase I clinical trial for HG-CT-1, a CAR-T therapy for acute myeloid leukemia, allowing dose escalation and the start of pediatric recruitment. This milestone signifies a de-risking step in the therapy’s development, potentially enhancing its efficacy and paving the way for broader clinical validation, which could positively impact the company’s market position and investor interest.

Hemogenyx Pharmaceuticals Expands Clinical Trial to Include Pediatric Patients

Hemogenyx Pharmaceuticals announced that the Institutional Review Board at MD Anderson Cancer Center has approved an amendment to their Phase I trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, to include pediatric patients. This expansion marks a significant milestone, broadening the potential patient population and demonstrating the company’s commitment to advancing treatment options in the pediatric setting, which may enhance their market positioning and support long-term growth.